These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27755552)

  • 1. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
    Chauffour A; Robert J; Veziris N; Aubry A; Pethe K; Jarlier V
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007857. PubMed ID: 32866170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
    Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.
    Bentoucha A; Robert J; Dega H; Lounis N; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3109-12. PubMed ID: 11600364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.